Latest diabetic neuropathy Stories
BALTIMORE, June 14, 2011 /PRNewswire/ -- Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that data from the Phase 2b trial of ARC-4558 for the treatment of pain associated with painful diabetic neuropathy (PDN) will be the subject of two poster presentations at upcoming medical meetings. The first poster will be presented at the American Diabetes Association's 71st Scientific Sessions, June 24-28,...
NEW YORK, May 16, 2011 /PRNewswire/ -- For National Neuropathy Week, May 16-20, The Neuropathy Association is launching a "Talk Neuropathy" campaign featuring patient-guided interviews with Association spokesperson and former star of screen and stage Rev. Mother Dolores Hart, O.S.B., Emmy-Award winning journalist Pia Lindstrom, and critically acclaimed author and poet Sarah Manguso. Using questions submitted by neuropathy patients for these high-profile advocates, the "Talk...
RICHMOND, Calif., April 26, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2011 financial results and accomplishments. For the first quarter ended March 31, 2011, Sangamo reported a consolidated net loss of $9.6 million, or $0.21 per share, compared to a net loss of $4.0 million, or $0.09 per share, for the same period in 2010. As of March 31, 2011, the company had cash, cash equivalents and marketable securities of $49.2 million. Revenues for...
Compounds helped nerve extensions re-grow faster in mouse studiesDrugs already in development to treat Alzheimer's disease may eventually be tapped for a different purpose altogether: re-growing the ends of injured nerves to relieve pain and paralysis. According to a new Johns Hopkins study, experimental compounds originally designed to combat a protein that builds up in Alzheimer's-addled brains appear to make crushed or cut nerve endings grow back significantly faster, a potential boon for...
(Ivanhoe Newswire) -- The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain -- the burning or tingling pain in the hands and feet that affects millions of people with diabetes.Diabetic nerve pain, or neuropathy, is caused by nerve damage. "When neuropathy strikes, it is painful and can disrupt sleep; because of this, it can also lead to mood changes and lower quality of life," lead guideline author Vera Bril, MD, FRCP,...
BRIDGEWATER, N.J. and TORONTO, Feb. 15, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic...
Gilad&Gilad LLC of Reseda (Los Angeles), California, has re-launched Neurofencine(TM), a first-of-its-kind nutraceutical supplement clinically proven for nerve resilience and pain-free nerve functions. Neurofencine(TM) targets unmet needs of millions of people who cope with circumstances affecting normal nerve functions. Reseda, CA (PRWEB) February 6, 2011 Neurofencine(TM) development is the outcome of breakthrough discoveries made and patented by the neuroscientist founders of...
RICHMOND, Calif., Feb. 2, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2010 financial results and accomplishments. For the fourth quarter ended December 31, 2010, Sangamo reported a consolidated net loss of $8.3 million, or $0.18 per share, compared to a net loss of $2.4 million, or $0.05 per share, for the same period in 2009. As of December 31, 2010, the company had cash, cash equivalents, marketable securities and interest...
Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease (COPD). The enzyme's action can be blocked by drugs whose safety has been shown in clinical trials for other diseases "“ a discovery that could improve therapies for the 510 million people worldwide suffering from asthma and COPD.The findings are from a University of Texas...
RICHMOND, Calif., Jan. 10, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN). The company expects to have efficacy data from this study in the second half of 2011. The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011....
